

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cryofocus Medtech (Shanghai) Co., Ltd.

康豐生物科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6922)

VOLUNTARY ANNOUNCEMENT

NMPA APPROVAL FOR MALIGNANT STENOSIS CRYOABLATION SYSTEM

This announcement is made by Cryofocus Medtech (Shanghai) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders of the Company and potential investors about the latest business development of the Group.

The Company is pleased to announce that on March 6, 2025, the Group’s Malignant Stenosis Cryoablation System (the “**Malignant Stenosis Cryoablation System**”), which is one of the Group’s respiratory intervention products and consists of a cryotherapy equipment and an airway cryoablation catheter, was granted approval by the National Medical Products Administration of the People’s Republic of China (國家藥品監督管理局) (the “**NMPA**”).

The Malignant Stenosis Cryoablation System is a self-developed cryoablation system indicated to ablate malignant airway tumor tissue and reduce the frequency of airway restenosis. During procedures, the Malignant Stenosis Cryoablation System ablates tumor cells in the lumen and luminal wall of the trachea with the ultra-low temperature generated by the cryoablation system, and then further destroys tumor cells through rewarming. The cryoablation balloon allows for more complete ablation of malignant tumors on a larger scale and delays restenosis time.

THE COMPANY CANNOT GUARANTEE THE FUTURE PROSPECTS OF THE MALIGNANT STENOSIS CRYOABLATION SYSTEM. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By order of the Board
Cryofocus Medtech (Shanghai) Co., Ltd.
Mr. LI Kejian
Chairman of the Board

Hong Kong, March 6, 2025

As at the date of this announcement, the board of directors of the Company comprises Mr. LI Kejian, Mr. ZHU Jun and Mr. LIU Wei as executive directors, Mr. LV Shiwen and Mr. ZHAO Chunsheng as non-executive directors, and Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan as independent non-executive directors.